MI-463 is a potent and selective inhibitor of the MDM2-p53 protein-protein interaction, making it a valuable tool in cancer research. It functions by disrupting the binding between MDM2 and the tumor suppressor protein p53, which leads to stabilization and activation of p53 in cancer cells that overexpress MDM2. This activation triggers cell cycle arrest and apoptosis, particularly in tumor cells with wild-type p53. It is primarily used in preclinical studies to evaluate the therapeutic potential of MDM2 inhibitors in various cancers, including sarcomas, leukemia, and solid tumors. MI-463 has shown promising antitumor activity in xenograft models, supporting its role as a lead compound for developing targeted cancer therapies. Its high selectivity and potency make it suitable for studying p53 pathway modulation and for combination therapy investigations with other anticancer agents.